JAK3-STAT pathway blocking benefits in experimental lupus nephritis
| dc.contributor.author | Ripoll Llagostera, Èlia | |
| dc.contributor.author | Ramon, Laura de | |
| dc.contributor.author | Bordignon Draibe, Juliana | |
| dc.contributor.author | Merino, Ana | |
| dc.contributor.author | Bolaños, Núria | |
| dc.contributor.author | Gomà, Montse | |
| dc.contributor.author | Cruzado, Josep Ma. | |
| dc.contributor.author | Grinyó Boira, Josep M. | |
| dc.contributor.author | Torras Ambròs, Joan | |
| dc.date.accessioned | 2018-02-20T09:46:03Z | |
| dc.date.available | 2018-02-20T09:46:03Z | |
| dc.date.issued | 2016-06-08 | |
| dc.date.updated | 2018-02-20T09:46:03Z | |
| dc.description | Es va publicar un erratum de l'article a: Arthritis Research & Therapy, 2016, vol. 18 , num. 1, p. 152 | |
| dc.description.abstract | Background: Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway and how CP-690,550 treatment influences LN outcome. Methods: Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and circulating cytokine changes. Results: CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli. We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating inflammatory cytokines were also reduced with treatment. Conclusions: On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune diseases. | |
| dc.format.extent | 12 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 666380 | |
| dc.identifier.issn | 1478-6362 | |
| dc.identifier.pmid | 27278657 | |
| dc.identifier.uri | https://hdl.handle.net/2445/120023 | |
| dc.language.iso | eng | |
| dc.publisher | BioMed Central | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s13075-016-1034-x | |
| dc.relation.ispartof | Arthritis Research & Therapy, 2016, vol. 18 , num. 1, p. 134 | |
| dc.relation.uri | https://doi.org/10.1186/s13075-016-1034-x | |
| dc.rights | cc-by (c) Ripoll Llagostera, Èlia et al., 2016 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | |
| dc.source | Articles publicats en revistes (Ciències Clíniques) | |
| dc.subject.classification | Lupus | |
| dc.subject.classification | Malalties autoimmunitàries | |
| dc.subject.classification | Citoquines | |
| dc.subject.classification | Ratolins (Animals de laboratori) | |
| dc.subject.other | Lupus | |
| dc.subject.other | Autoimmune diseases | |
| dc.subject.other | Cytokines | |
| dc.subject.other | Mice (Laboratory animals) | |
| dc.title | JAK3-STAT pathway blocking benefits in experimental lupus nephritis | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 2 de 2